Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Last week marked the 90 day deadline since the National Institute for Health and Care Excellence (NICE) issued its Technology Appraisal Guidance, stipulating that adults with type 2 diabetes should have access via the NHS to dapagliflozin as dual therapy in combination with metformin, and in combination with insulin with or without other oral antidiabetic drugs.1,3
NICE has advised that dapagliflozin be used in-line with NICE guidance CG87 for the use of dipeptidyl peptidase-4 (DPP-4) inhibitors in dual therapy with metformin.4 NICE recommended dapagliflozin to be used in combination with metformin instead of a sulphonylurea (SU) in certain patients.1 These are patients for whom an SU is not tolerated / contraindicated or who are at significant risk of hypoglycaemia or its consequences.1 Furthermore, the NICE recommendations state that the addition of dapagliflozin to metformin may be preferable to a thiazolidinedione if further weight gain is a concern.1 Dapagliflozin is not licensed for weight loss. The full NICE guidance can be accessed at: www.nice.org.uk.
http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=79283#.UkwlXIa2aSo
NICE has advised that dapagliflozin be used in-line with NICE guidance CG87 for the use of dipeptidyl peptidase-4 (DPP-4) inhibitors in dual therapy with metformin.4 NICE recommended dapagliflozin to be used in combination with metformin instead of a sulphonylurea (SU) in certain patients.1 These are patients for whom an SU is not tolerated / contraindicated or who are at significant risk of hypoglycaemia or its consequences.1 Furthermore, the NICE recommendations state that the addition of dapagliflozin to metformin may be preferable to a thiazolidinedione if further weight gain is a concern.1 Dapagliflozin is not licensed for weight loss. The full NICE guidance can be accessed at: www.nice.org.uk.
http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=79283#.UkwlXIa2aSo